Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy

Abstract

Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (TR1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.

Keywords

• Immunotherapy
• checkpoint inhibitor
• monoclonal antibody
• immunogenic cell death